Myelofibrosis
Myelofibrosis (MF) is a disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases. Over time, this leads to progressive bone marrow failure. Under normal conditions, the bone marrow provides a fine network of fibres on which the stem cells can divide and grow.&nbsp;
&nbsp;
Myelofibrosis Epidemiology Segmentation in the 
&nbsp;
<ul>
<li class="ql-align-justify">Total Prevalent Cases</li>
<li class="ql-align-justify">Total Diagnosed Prevalent cases</li>
<li class="ql-align-justify">Type-specific Prevalent Cases</li>
<li class="ql-align-justify">Myelofibrosis cases Based on Risk Stratification</li>
<li class="ql-align-justify">Age-specific Prevalent Cases</li>
<li class="ql-align-justify">Myelofibrosis Cases Based on Molecular Alterations</li>
<li class="ql-align-justify">Treatment Eligible Pool</li>
<li class="ql-align-justify">Transplant Eligible/Ineligible Cases</li>
</ul>
&nbsp;
<a style="color: black;" href="https://www.delveinsight.com/report-store/myelofibrosis-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Myelofibrosis Epidemiological Insights Observed in the 7MM</a> (2021)
The total number of incident cases of Myelofibrosis observed in the 7MM was observed to be 39K in the year 2021
The highest diagnosed Myelofibrosis population accounting for 20K cases, was found in the United States, followed by EU5 (14K) and Japan (5K) in the year 2021.&nbsp;
&nbsp;
<a style="color: black;" href="https://www.delveinsight.com/report-store/myelofibrosis-market" target="_blank" rel="noopener noreferrer">Myelofibrosis Market Insight</a>
The market size of Myelofibrosis is expected to grow with a CAGR of 7.3% during the study period (2019-2032)
&nbsp;
Myelofibrosis Market Strengths
Myelofibrosis is a rare form of hematologic cancer; thus, companies developing its treatment options can possess several advantages like market exclusivities, premium pricing, trial subsidy, and other benefits from the government bodies for R&amp;D. 
&nbsp;
Myelofibrosis Market Opportunities
Therapy options for patients with comorbidities such as anemia and thrombocytopenia remain an unmet need, but emerging treatments may offer additional benefits for difficult-to-treat patients. 
&nbsp;
<a style="color: black;" href="https://www.delveinsight.com/report-store/myelofibrosis-pipeline-insight" target="_blank" rel="noopener noreferrer">Myelofibrosis Emerging Drugs and Key Companies</a>
&nbsp;
<ul>
<li class="ql-align-justify">Imetelstat (GRN163L): Geron Corporation</li>
<li class="ql-align-justify">Navitoclax (ABT-263): AbbVie</li>
<li class="ql-align-justify">Momelotinib: Sierra Oncology</li>
<li class="ql-align-justify">GB2064: Galecto Biotech</li>
<li class="ql-align-justify">Elraglusib (9-ING-41): Actuate Therapeutics</li>
<li class="ql-align-justify">Navtemadlin (KRT-232): Kartos Therapeutics</li>
<li class="ql-align-justify">TL-895: Telios Pharma</li>
<li class="ql-align-justify">Tagraxofusp (ELZONRIS/SL-401): Menarini Group</li>
<li class="ql-align-justify">Smac Mimetic LCL161: Novartis Pharmaceuticals</li>
<li class="ql-align-justify">Ilginatinib (NS-018): NS Pharma</li>
<li class="ql-align-justify">Selinexor: Karyopharm Therapeutics</li>
<li class="ql-align-justify">Itacitinib (INCB039110): Incyte Corporation</li>
<li class="ql-align-justify">Parsaclisib (INCB050465): Incyte</li>
<li class="ql-align-justify">REBLOZYL (Luspatercept/ACE-536): Celgene/Bristol Myers Squibb</li>
<li class="ql-align-justify">Pelabresib: MorphoSys</li>
<li class="ql-align-justify">Imago BioSciences</li>
<li class="ql-align-justify">Zinpentraxin alfa: Roche</li>
</ul>
&nbsp;

Myelofibrosis Market

Myelofibrosis Market Infographics

Myelofibrosis Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape